系统性红斑狼疮的药物监测。
Drug monitoring in systemic lupus erythematosus.
机构信息
Johns Hopkins University School of Medicine, Department of Medicine, Division of Rheumatology, 1830 E. Monument Street, Suite 7500, Baltimore, MD, 21205, USA.
出版信息
Curr Opin Pharmacol. 2022 Jun;64:102225. doi: 10.1016/j.coph.2022.102225. Epub 2022 Apr 28.
Abstract
Therapeutic drug monitoring (TDM) is not yet accepted by systemic lupus erythematosus (SLE) treatment guidelines. Studies in SLE, however, have proven benefit in three areas: identification of non-adherence or poor adherence; targets for clinical benefit; and ranges of toxicity. This review covers the data on three medications commonly used for SLE, drawing on studies from both the SLE and non-SLE literature.
摘要
治疗药物监测（TDM）尚未被系统性红斑狼疮（SLE）治疗指南所接受。然而，SLE 领域的研究已经证明了在三个方面的益处：识别不依从或依从性差；临床获益的目标；以及毒性范围。这篇综述涵盖了三种常用于 SLE 的药物的数据，借鉴了 SLE 和非 SLE 文献中的研究。
相似文献
1
Drug monitoring in systemic lupus erythematosus.系统性红斑狼疮的药物监测。
Curr Opin Pharmacol. 2022 Jun;64:102225. doi: 10.1016/j.coph.2022.102225. Epub 2022 Apr 28.
2
Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus.系统性红斑狼疮中免疫调节药物的治疗监测
Expert Rev Clin Immunol. 2017 Jan;13(1):35-41. doi: 10.1080/1744666X.2016.1212659. Epub 2016 Jul 22.
3
Adherence to treatment in systemic lupus erythematosus patients.系统性红斑狼疮患者的治疗依从性。
Best Pract Res Clin Rheumatol. 2013 Jun;27(3):329-40. doi: 10.1016/j.berh.2013.07.001.
4
Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.羟氯喹水平与以西班牙裔为主的系统性红斑狼疮患者疾病活动度的相关性研究。
Lupus. 2019 Jun;28(7):862-867. doi: 10.1177/0961203319851558. Epub 2019 May 24.
5
Interventions for cutaneous disease in systemic lupus erythematosus.治疗系统性红斑狼疮皮肤病变的干预措施。
Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2.
6
Hydroxychloroquine and immunosuppressant adherence patterns and their association with subsequent hospitalization rates among children with systemic lupus erythematosus.羟氯喹和免疫抑制剂的用药依从性模式及其与系统性红斑狼疮患儿随后住院率的关系。
Semin Arthritis Rheum. 2022 Oct;56:152042. doi: 10.1016/j.semarthrit.2022.152042. Epub 2022 Jun 8.
7
Association of patient copayment and medication adherence in systemic lupus erythematosus.患者自付额与系统性红斑狼疮药物依从性的关联。
Lupus Sci Med. 2023 Oct;10(2). doi: 10.1136/lupus-2023-000966.
8
Systemic lupus erythematosus: review of synthetic drugs.系统性红斑狼疮：合成药物综述
Expert Opin Pharmacother. 2015;16(18):2793-806. doi: 10.1517/14656566.2015.1101448. Epub 2015 Oct 19.
9
Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.新诊断系统性红斑狼疮患者的纵向治疗模式及相关结局
Clin Ther. 2016 Mar;38(3):610-24. doi: 10.1016/j.clinthera.2016.01.016. Epub 2016 Feb 19.
10
Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada.加拿大系统性红斑狼疮的诊断、监测和治疗中的实践差异。
J Rheumatol. 2018 Oct;45(10):1440-1447. doi: 10.3899/jrheum.171307. Epub 2018 Aug 1.
引用本文的文献
1
Therapeutic Hydroxychloroquine Blood Levels Are Associated With Fewer Hospitalizations and Possible Reduction of Health Disparities in Lupus.羟氯喹的治疗血药浓度与减少狼疮患者住院治疗相关，且可能减少健康差异。
Arthritis Care Res (Hoboken). 2024 Dec;76(12):1606-1616. doi: 10.1002/acr.25422. Epub 2024 Oct 1.
2
A Bitter Pill to Swallow: The Challenge of Medication Nonadherence in Systemic Lupus Erythematosus.难以下咽的苦药：系统性红斑狼疮患者药物治疗依从性面临的挑战
J Rheumatol. 2024 Sep 1;51(9):841-844. doi: 10.3899/jrheum.2024-0654.
3
Mendelian randomization analysis reveals a protective association between genetically predicted systemic lupus erythematosus and renal cell carcinoma.孟德尔随机化分析显示，遗传预测的系统性红斑狼疮与肾细胞癌之间存在保护关联。
Medicine (Baltimore). 2024 Mar 15;103(11):e37545. doi: 10.1097/MD.0000000000037545.
4
Therapeutic Drug Monitoring in Patients with Systemic Lupus Erythematosus: Utility and Gaps.系统性红斑狼疮患者的治疗药物监测：效用与差距
J Clin Med. 2024 Jan 13;13(2):451. doi: 10.3390/jcm13020451.
本文引用的文献
1
American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity.美国风湿病学会、美国皮肤病学会、风湿病皮肤病学会和美国眼科学会 2020 年关于羟氯喹视网膜毒性的联合声明
Arthritis Rheumatol. 2021 Jun;73(6):908-911. doi: 10.1002/art.41683. Epub 2021 Apr 26.
2
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.羟氯喹血药浓度与系统性红斑狼疮血栓风险降低相关。
Arthritis Rheumatol. 2021 Jun;73(6):997-1004. doi: 10.1002/art.41621. Epub 2021 May 2.
3
Hydroxychloroquine levels in patients with systemic lupus erythematosus: whole blood is preferable but serum levels also detect non-adherence.系统性红斑狼疮患者羟氯喹的血药浓度：全血优于血清，但也能检测到不依从性。
Arthritis Res Ther. 2020 Sep 25;22(1):223. doi: 10.1186/s13075-020-02291-z.
4
Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis.系统性红斑狼疮患者器官损伤与死亡风险的相关性：一项系统评价和荟萃分析。
BMJ Open. 2020 May 21;10(5):e031850. doi: 10.1136/bmjopen-2019-031850.
5
Hydroxychloroquine and Mortality Among Patients With Systemic Lupus Erythematosus in the General Population.羟氯喹与普通人群中系统性红斑狼疮患者的死亡率。
Arthritis Care Res (Hoboken). 2021 Aug;73(8):1219-1223. doi: 10.1002/acr.24255. Epub 2021 Jul 7.
6
Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.监测系统性红斑狼疮患者羟氯喹水平的临床意义：系统评价和荟萃分析。
Arthritis Care Res (Hoboken). 2021 May;73(5):707-716. doi: 10.1002/acr.24155. Epub 2021 Mar 30.
7
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.羟氯喹血药浓度可预测羟氯喹视网膜病变。
Arthritis Rheumatol. 2020 Mar;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7.
8
Incidence of blindness in a population of rheumatic patients treated with hydroxychloroquine.接受羟氯喹治疗的风湿性疾病患者群体中的失明发生率。
Rheumatol Adv Pract. 2019 Apr 15;3(1):rkz009. doi: 10.1093/rap/rkz009. eCollection 2019.
9
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.NUDT15 基因变异与炎症性肠病患者硫嘌呤诱导的骨髓抑制相关。
JAMA. 2019 Feb 26;321(8):773-785. doi: 10.1001/jama.2019.0709.
10
Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.基于 TPMT 和 NUDT15 基因型的硫嘌呤药物剂量调整：临床药物遗传学实施联盟指南 2018 年更新版。
Clin Pharmacol Ther. 2019 May;105(5):1095-1105. doi: 10.1002/cpt.1304. Epub 2019 Jan 20.
Zotero 插件